ArticleslgStudy

science

Hanneke Schuitemaker

Hanneke Schuitemaker is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Hanneke Schuitemaker rather than just read about it. In short: Hanneke Schuitemaker is a Dutch virologist, the Global Head of Viral Vaccine Discovery and Translational Medicine at Johnson & Johnson's Janssen Vaccines & Prevention, and a professor of virology at the Amsterdam University Medical Centers of the University of Amsterdam (since 2004). She has been involved in the development of Janssen's Ebola vaccine and is involved in the development of a universal flu vaccine, HIV…

Hanneke Schuitemaker — main illustration
Hanneke Schuitemaker — illustration

Key takeaways

  • Hanneke Schuitemaker belongs to science; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect Hanneke Schuitemaker to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of Hanneke Schuitemaker from memory before moving on to harder problems.

Reference excerpt

Hanneke Schuitemaker is a Dutch virologist, the Global Head of Viral Vaccine Discovery and Translational Medicine at Johnson & Johnson's Janssen Vaccines & Prevention, and a professor of virology at the Amsterdam University Medical Centers of the University of Amsterdam (since 2004). She has been involved in the development of Janssen's Ebola vaccine and is involved in the development of a universal flu vaccine, HIV vaccine, RSV vaccine and COVID-19 vaccine.

Early life and education Schuitemaker (1964) grew up in the Netherlands. Her mother was a bookkeeper and her father was an electrical engineer. As a child she was fascinated by medicine, and after earning her undergraduate degree she completed a PhD programme in AIDS pathogenesis at the University of Amsterdam.

Research and career Schuitemaker started to research HIV/AIDS in 1989. Whilst interested in the virus itself, Schuitemaker also wanted to learn more about the patients who suffered from the disease, and took part in a patient outreach program. Her interactions in this program strengthened her motivation to better understand the disease, help find a vaccine and treatments. She studied the pathogenesis of HIV-1 throughout her career. Her early research focussed on whether HIV could infect other cells in the body than just T cells, including cells in the brain and lungs. She started working at Sanquin, the Netherlands blood supply foundation based in Amsterdam, where she was made Head of the department of Clinical Viro-Immunology in 1998. Schuitemaker has been involved in policy, and has held advisory positions on several vaccine charities. From 2003 to 2004, she was a visiting scientist at the La Jolla Scripps Research Institute. Schuitemaker joined the Academic Medical Center in Amsterdam in 2008, where she was made Chair of Experimental Immunology. She moved to Crucell in 2010, which, at the time, was an independent biotechnology company. Two weeks later, Crucell was acquired by Janssen Vaccines, part of Johnson & Johnson. She was appointed Global Head of Viral Vaccines Discovery and Translational Medicine. At Janssen, Schuitemaker worked on the universal flu vaccine. She returned to working on vaccinations to protect against HIV-1. Schuitemaker demonstrated the efficacy of the adenovirus/protein vaccines against simian immunodeficiency virus in rhesus macaques. In 2018, Schuitemaker's vaccine regime was shown to induce an immune response to HIV in humans. Results of Imbokodo, an investigation into the potential for this vaccine to save the lives of thousands of young women in Sub-Saharan Africa, are expected in 2021. Another study, Mosaico, will see 3,800 individuals taking part in a Phase 3 clinical trial of the vaccine. During the COVID-19 pandemic Janssen looked to develop a COVID-19 vaccine. Their approach started with a single viral genome, which was being tested as of March 2020. Schuitemaker estimated that it would take between 12 and 18 months to manufacture a vaccine. Early in the COVID-19 pandemic, Schuitemaker announced Johnson & Johnson's ambition to develop a vaccine against the unknown infectious disease. Her team's approach started with the discovery of the genetic code of SARS-CoV-2, the cause of the disease COVID-19. The various vaccine candidates have been tested from March 2020. In mid-May, she announced that Janssen's most hopeful vaccine variant will be tested on humans in July 2020. In November 2020, Jansen Vaccines announced that the production of the COVID vaccine was delayed by several months due to the occurrence of an unknown disease in one test subject in phase 3. The US regulator FDA approved the Johnson & Johnson COVID-19 vaccine for use on February 27, 2021. Approval by the European Medicines Agency was given on March 11.

Selected publications Fouchier, R A; Groenink, M; Kootstra, N A; Tersmette, M; Huisman, H G; Miedema, F; Schuitemaker, H (1992). "Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule". Journal of Virology. 66 (5): 3183–3187. doi:10.1128/jvi.66.5.3183-3187.1992. ISSN 0022-538X. PMC 241084. PMID 1560543. van't Wout, A B; Kootstra, N A; Mulder-Kampinga, G A; Albrecht-van Lent, N; Scherpbier, H J; Veenstra, J; Boer, K; Coutinho, R A; Miedema, F; Schuitemaker, H (1994-11-01). "Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission". Journal of Clinical Investigation. 94 (5): 2060–2067. doi:10.1172/jci117560. ISSN 0021-9738. PMC 294642. PMID 7962552. "Glycan recognition on HIV env by broadly neutralizing antibodies (bNAbs)". Science-Business EXchange. 7 (40): 1192. 2014. doi:10.1038/scibx.2014.1192. ISSN 1945-3477.

Personal life Schuitemaker has three sons.

References

Illustrations

Hanneke Schuitemaker illustration

Worked examples

Example 1 — a first encounter with Hanneke Schuitemaker

Start with the simplest possible case. Write down what Hanneke Schuitemaker claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Hanneke Schuitemaker before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Hanneke Schuitemaker ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Hanneke Schuitemaker

In research
Hanneke Schuitemaker appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses Hanneke Schuitemaker in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
Hanneke Schuitemaker is common in secondary-school and first-year university syllabi. It links to neighbouring topics 1964 births, 20th-century Dutch scientists, 20th-century Dutch women, so understanding it makes those chapters shorter.
In everyday life
Look for Hanneke Schuitemaker outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.
Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Hanneke Schuitemaker” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Hanneke Schuitemaker in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what Hanneke Schuitemaker means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain Hanneke Schuitemaker out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Hanneke Schuitemaker in simple terms?

Hanneke Schuitemaker is a Dutch virologist, the Global Head of Viral Vaccine Discovery and Translational Medicine at Johnson & Johnson's Janssen Vaccines & Prevention, and a professor of virology at the Amsterdam University Medical Centers of the University of Amsterdam (since 2004). She has been i…

Why does Hanneke Schuitemaker matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Hanneke Schuitemaker?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Hanneke Schuitemaker.

Tags

  • 1964 births
  • 20th-century Dutch scientists
  • 20th-century Dutch women
  • 20th-century Dutch women scientists
  • 21st-century Dutch scientists
  • 21st-century Dutch women scientists
  • COVID-19 researchers
  • Dutch medical researchers
  • Dutch virologists
  • Dutch women scientists
  • Ebola researchers
  • HIV/AIDS researchers

Keep exploring